Skip to content
Screener

Travere Therapeutics, Inc. TVTX Business Segments — Internal personnel costs

Similar metrics at other companies

The Buckle logo
BKEReportable Segment — Personnel Costs
$72.64M+11.9%
Andersen Group logo
ANDGReportable Segment — Personnel costs
$175.69M+51.6%
Castle Biosciences logo
CSTLReportable Segment — Personnel costs
$58.37M+11.8%
CS Disco logo
LAWReportable Segment — Personnel costs
$29.44M+3.0%
Lifecore Biomedical, Inc. logo
LFCRReportable Segment — Personnel costs
$10.95M
KVH Industries logo
KVHIReportable Segment — Personnel costs
$3.63M+7.3%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept tvtx:InternalPersonnelCostsForResearchAndDevelopment.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Cost of goods sold1,9504,679
Research and development:
External research and development27,72822,355
Internal personnel costs24,52520,102
Other research and development4,8414,432
Total research and development57,09446,889
Selling, general and administrative80,25460,413
Royalty expense24,81612,425

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s business segments — internal personnel costs?
Travere Therapeutics, Inc. (TVTX) reported business segments — internal personnel costs of $24.53M in Q1 2026.
How has Travere Therapeutics, Inc.'s business segments — internal personnel costs changed year-over-year?
Travere Therapeutics, Inc.'s business segments — internal personnel costs increased by 22.0% year-over-year, from $20.1M to $24.53M.
What is the long-term trend for Travere Therapeutics, Inc.'s business segments — internal personnel costs?
Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — internal personnel costs has grown at a 1.9% compound annual growth rate (CAGR), from $75.66M to $80.09M.
What does business segments — internal personnel costs mean?
This metric represents the compensation and benefits expenses for internal staff dedicated to research and development activities. It measures the company's investment in its internal scientific expertise and human capital necessary for drug discovery and clinical oversight.

Ask your AI about Travere Therapeutics, Inc.'s business segments — internal personnel costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude